References •
heart failure clinical trials. European Journal of Heart Failure , 22 (6), 1032–1042. https://doi. org/10.1002/ejhf.1818 • Khan, M. S., Sreenivasan, J., Lateef, N., Abougergi, M. S., Greene, S. J., Ahmad, T., Anker, S. D., Fonarow, G. C., & Butler, J. (2021). Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circulation. Heart Failure , 14 (4), e008335. https://doi.org/10.1161/ CIRCHEARTFAILURE.121.008335 • Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., Devereux, R. B., & Zannad, F. (2020). Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension , 75 (1), 23– 32. https://doi.org/10.1161/HYPERTENSIONAHA.119.14057 • Kostis, W. J., Shetty, M., Chowdhury, Y. S., & Kostis, J. B. (2018). ACE Inhibitor-Induced Angioedema: A Review. Current Hypertension Reports , 20 (7), 55. https://doi.org/10.1007/ s11906-018-0859-x • Kumbhani, D. (2021, October 25). Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist . American College of Cardiology. https://www.acc.org/ latest-in-cardiology/clinical-trials/2014/06/04/12/40/http%3a%2f%2fwww.acc.org%2flatest- in- cardiology%2fclinical-trials%2f2014%2f06%2f04%2f12%2f40%2ftopcat • Lam, C., Arnott, C., & Beale, A. (2019, December 17). Sex Differences in Heart Failure . American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to- remember/2019/12/17/13/36/http%3a%2f%2fwww.acc.org%2flatest-in- cardiology%2ften- points-to-remember%2f2019%2f12%2f17%2f13%2f36%2fsex- differences-in-heart-failure • Lesyuk, W., Kriza, C., & Kolominsky-Rabas, P. (2018). Cost-of-illness studies in heart failure: A systematic review 2004–2016. BMC Cardiovascular Disorders , 18 (1), 74. https://doi. org/10.1186/s12872-018-0815-3 • Libby, P., Bonow, R., Mann, D., Tomaselli, G. F., Bhatt, D. L., Solomon, S. D., & Braunwald, E. (2021). Braunwald’s Heart Disease, 2 Vol Set, 12th Edition (12th ed., Vol. 1–2). Elsevier. • Lopes, R. D., Rordorf, R., De Ferrari, G. M., Leonardi, S., Thomas, L., Wojdyla, D. M., Ridefelt, P., Lawrence, J. H., De Caterina, R., Vinereanu, D., Hanna, M., Flaker, G., Al- Khatib, S. M., Hohnloser, S. H., Alexander, J. H., Granger, C. B., & Wallentin, L. (2018). Digoxin and Mortality in Patients With Atrial Fibrillation. Journal of the American College of Cardiology , 71 (10), 1063–1074. https://doi.org/10.1016/j.jacc.2017.12.060 • Maack, C., Lehrke, M., Backs, J., Heinzel, F. R., Hulot, J.-S., Marx, N., Paulus, W. J., Rossignol, P., Taegtmeyer, H., Bauersachs, J., Bayes-Genis, A., Brutsaert, D., Bugger, H., Clarke, K., Cosentino, F., De Keulenaer, G., Dei Cas, A., González, A., Huelsmann, M., … Heymans, S. (2018). Heart failure and diabetes: Metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal , 39 (48), 4243–4254. https://doi.org/10.1093/eurheartj/ehy596 • Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., Motiwala, S. R., Oliveros, E., Patterson, J. H., Walsh, M. N., Wasserman, A., Yancy, C. W., & Youmans, Q. R. (2021). 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology , 77 (6), 772–810. https://doi.org/10.1016/j. jacc.2020.11.022 • McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., … Langkilde, A.-M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine , 381 (21), 1995–2008. https://doi.org/10.1056/ NEJMoa1911303 • Nayak, A., Hicks, A. J., & Morris, A. A. (2020). Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients. Circulation: Heart Failure , 13 (8), e007264. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007264 • Oh, S. W., & Han, S. Y. (2015). Loop Diuretics in Clinical Practice. Electrolytes & Blood Pressure : E & BP , 13 (1), 17–21. https://doi.org/10.5049/EBP.2015.13.1.17 • Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., … Zannad, F. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine , 383 (15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190 Rech, M., Barandiarán Aizpurua, A., van Empel, V., van Bilsen, M., & Schroen, B. (2018). Pathophysiological understanding of HFpEF: MicroRNAs as part of the puzzle. Cardiovascular Research , 114 (6), 782–793. https:// doi.org/10.1093/cvr/cvy049 • Roger, V. L. (2021). Epidemiology of Heart Failure. Circulation Research , 128 (10), 1421– 1434. https://doi.org/10.1161/CIRCRESAHA.121.318172 • Sano, M. (2018). A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. Journal of Cardiology , 71 (5), 471–476. https://doi.org/10.1016/j. jjcc.2017.12.004 • Schwinger, R. H. G. (2021). Pathophysiology of heart failure. Cardiovascular Diagnosis and Therapy , 11 (1), 263–276. https://doi.org/10.21037/cdt-20-302 • Serenelli, M., Jackson, A., Dewan, P., Jhund, P. S., Petrie, M. C., Rossignol, P., Campo, G., Pitt, B., Zannad, F., Ferreira, J. P., & McMurray, J. J. V. (2020). Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure , 8 (3), 188–198. https://doi.org/10.1016/j.jchf.2019.09.011 • Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017). Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. Journal of the American College of Cardiology , 70 (20), 2476–2486. https://doi.org/10.1016/j.jacc.2017.08.074 Sharma, K., Mok, Y., Kwak, L., Agarwal, S. K., Chang, P. P., Deswal, A., Shah, A. M., Kitzman, D. W., Wruck, L. M., Loehr, L. R., Heiss, G., Coresh, J., Rosamond, W. D., Solomon, S. D., Matsushita, K., & Russell, S. D. (2020). Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease , 9 (19), e014669. https://doi.org/10.1161/JAHA.119.014669 • Shim, J.-S., SONG, W.-J., & MORICE, A. H. (2020). Drug-Induced Cough. Physiological Research , 69 (Suppl 1), S81–S92. https://doi.org/10.33549/physiolres.934406 Silverman, D. N., Plante, T. B., Infeld, M., Callas, P. W., Juraschek, S. P., Dougherty, G. B., & Meyer, M. (2019). Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction. JAMA Network Open , 2 (12), e1916598. https://doi.org/10.1001/ jamanetworkopen.2019.16598 • Solomon, S. D., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Lindholm, D., Wilderäng, U., Öhrn, F., Claggett, B., Langkilde, A. M., Petersson, M., & McMurray, J. J. V. (2021). Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial. European Journal of Heart Failure , 23 (7), 1217–1225. https://doi.org/10.1002/ ejhf.2249 • Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., … Lefkowitz, M. P. (2019). Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine , 381 (17), 1609–1620. https://doi.org/10.1056/NEJMoa1908655 • Urbich, M., Globe, G., Pantiri, K., Heisen, M., Bennison, C., Wirtz, H. S., & Di Tanna, G. L. (2020). A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics , 38 (11), 1219–1236. https://doi.org/10.1007/s40273-020- 00952-0 • Van Nuys, K. E., Xie, Z., Tysinger, B., Hlatky, M. A., & Goldman, D. P. (2018). Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities. JACC. Heart Failure , 6 (5), 401–409. https://doi.org/10.1016/j.jchf.2017.12.006 • Vasan, R. S., Enserro, D. M., Beiser, A. S., & Xanthakis, V. (2022). Lifetime Risk of Heart Failure Among Participants in the Framingham Study. Journal of the American College of Cardiology , 79 (3), 250–263. https://doi.org/10.1016/j.jacc.2021.10.043 • Verma, S., & McMurray, J. J. V. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia , 61 (10), 2108–2117. https://doi.org/10.1007/ s00125-018-4670-7
Alsumali, A., Djatche, L. M., Briggs, A., Liu, R., Diakite, I., Patel, D., Wang, Y., & Lautsch, D. (2021). Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. Pharmacoeconomics , 39 (11), 1343–1354. https://doi.org/10.1007/s40273-021- 01091-w • American Diabetes Association. (2021). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care , 44 (Supplement 1), S125– S150. https://doi.org/10.2337/dc21-S010 • Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez- Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., … Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine , 0 (0), null. https://doi.org/10.1056/ NEJMoa2107038 • Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M. (2020). Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine , 382 (20), 1883–1893. https://doi.org/10.1056/ NEJMoa1915928 • Baliga, R. (2017, November 6). Heart Failure With Mid-Range Ejection Fraction . American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to- remember/2017/11/06/15/38/http%3a%2f%2fwww.acc.org%2flatest-in- cardiology%2ften- points-to-remember%2f2017%2f11%2f06%2f15%2f38%2fheart- failure-with-mid-range- ejection-fraction • Balmforth, C., Simpson, J., Shen, L., Jhund, P. S., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V., Solomon, S. D., Swedberg, K., Zile, M. R., Packer, M., & McMurray, J. J. V. (2019). Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC: Heart Failure , 7 (6), 457–465. https://doi.org/10.1016/j. jchf.2019.02.015 • Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., Isasi, C. R., Jiménez, M. C., Jordan, L. C., Judd, S. E., Lackland, D., Lichtman, J. H., Lisabeth, L., Liu, S., Longenecker, C. T., … Muntner, P. (2017). Heart Disease and Stroke Statistics—2017 Update. Circulation , 135 (10), e146– e603. https://doi.org/10.1161/CIR.0000000000000485 • Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C., Khan, S. S., Kissela, B. M., Knutson, K. L., … null, null. (2019). Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation , 139 (10), e56–e528. https://doi.org/10.1161/ CIR.0000000000000659 • Bhatt, D. L. (2021, May 17). ACC.21 Presentation Slides | SOLOIST and SCORED . American College of Cardiology. https://www.acc.org/education-and-meetings/image- and-slide- gallery/http%3a%2f%2fwww.acc.org%2feducation-and-meetings%2fimage- and-slide- gallery%2fmedia-detail%3fid%3db0ee906fd2d34b6aa29900bce0681b8e Bozkurt, B., Hershberger, R. E., Butler, J., Grady, K. L., Heidenreich, P. A., Isler, M. L., Kirklin, J. K., & Weintraub, W. S. (2021). 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). Circulation: Cardiovascular Quality and Outcomes , 14 (4), e000102. https:// doi.org/10.1161/HCQ.0000000000000102 • Brewster, L. M. (2019). Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: A cross-European survey. ESC Heart Failure , 6 (3), 487– 498. https://doi.org/10.1002/ehf2.12421 • Briongos-Figuero, S., Estévez, A., Pérez, M. L., Martínez-Ferrer, J. B., García, E., Viñolas, X., Arenal, Á., Alzueta, J., & Muñoz-Aguilera, R. (2019). Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. ESC Heart Failure , 7 (1), 279–283. https://doi.org/10.1002/ehf2.12548 • Brown, T., Gonzalez, J., & Monteleone, C. (2017). Angiotensin-converting enzyme inhibitor– induced angioedema: A review of the literature. The Journal of Clinical Hypertension , 19 (12), 1377–1382. https://doi.org/10.1111/jch.13097 • Carlisle, M. A., Fudim, M., DeVore, A. D., & Piccini, J. P. (2019). Heart Failure and Atrial Fibrillation, Like Fire and Fury. JACC: Heart Failure , 7 (6), 447–456. https://doi.org/10.1016/j. jchf.2019.03.005 • CDC. (2020, September 8). Heart Failure | cdc.gov . Centers for Disease Control and Prevention. https://www.cdc.gov/heartdisease/heart_failure.htm • Chandra, A., Skali, H., Claggett, B., Solomon, S. D., Rossi, J. S., Russell, S. D., Matsushita, K., Kitzman, D. W., Konety, S. H., Mosley, T. H., Chang, P. P., & Shah, A. M. (2022). Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. Journal of the American College of Cardiology , 79 (4), 355–368. https://doi.org/10.1016/j. jacc.2021.11.024 • Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., Pratt, N., Reich, C. G., Madigan, D., You, S. C., Ryan, P. B., & Hripcsak, G. (2021). Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension , 78 (3), 591– 603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667 • Cleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J., Coats, A. J. S., Manzano, L., McMurray, J. J. V., Ruschitzka, F., van Veldhuisen, D. J., von Lueder, T. G., Böhm, M., Andersson, B., Kjekshus, J., Packer, M., Rigby, A. S., Rosano, G., Wedel, H., Hjalmarson, Å., … Kotecha, D. (2018). Beta-blockers for heart failure with reduced, mid- range, and preserved ejection fraction: An individual patient-level analysis of double- blind randomized trials. European Heart Journal , 39 (1), 26–35. https://doi.org/10.1093/eurheartj/ ehx564 • Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., Terra, S. G., Cater, N. B., Gantz, I., McGuire, D. K., & VERTIS CV Investigators. (2020). Efficacy of Ertugliflozin on Heart Failure- Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation , 142 (23), 2205–2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255 FDA Advisory Committee. (2020). FDA Briefing Document. Cardiovascular and Renal Drugs Advisory Committee Meeting. NDA 207620. Sacubitril/Valsartan . https://www.fda.gov/media/144377/download • Ferreira, J. P., Rossello, X., Eschalier, R., McMurray, J. J. V., Pocock, S., Girerd, N., Rossignol, P., Pitt, B., & Zannad, F. (2019). MRAs in Elderly HF Patients: Individual Patient-Data Meta- Analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC: Heart Failure , 7 (12), 1012–1021. https://doi.org/10.1016/j.jchf.2019.08.017 • Gibson, G., Blumer, V., Mentz, R. J., & Lala, A. (2021, July 13). Universal Definition and Classification of Heart Failure: A Step in the Right Direction from Failure to Function . American College of Cardiology. https://www.acc.org/latest-in- cardiology/ articles/2021/07/12/12/31/http%3a%2f%2fwww.acc.org%2flatest-in- cardiology%2farticles% 2f2021%2f07%2f12%2f12%2f31%2funiversal-definition-and- classification-of-heart-failure • Greene, S. J., Butler, J., Albert, N. M., DeVore, A. D., Sharma, P. P., Duffy, C. I., Hill, C. L., McCague, K., Mi, X., Patterson, J. H., Spertus, J. A., Thomas, L., Williams, F. B., Hernandez, A. F., & Fonarow, G. C. (2018). Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. Journal of the American College of Cardiology , 72 (4), 351–366. https://doi.org/10.1016/j.jacc.2018.04.070 • Gupta, R., Testani, J., & Collins, S. (2019). Diuretic Resistance in Heart Failure. Current Heart Failure Reports , 16 (2), 57–66. https://doi.org/10.1007/s11897-019-0424-1 Herman, L., Bruss, Z., & Tivakaran, V. (2021, July 26). Hydralazine . StatPearls. https://www.statpearls. com/ArticleLibrary/viewarticle/23063 • Januzzi, J. (2019, November 16). Canagliflozin Cardiovascular Assessment Study . American College of Cardiology. https://www.acc.org/latest-in-cardiology/clinical- trials/2017/06/12/16/25/http%3a%2f%2fwww.acc.org%2flatest-in- cardiology%2fclinical-trial s%2f2017%2f06%2f12%2f16%2f25%2fcanvas • Kato, E. T., Silverman, M. G., & Mosenzon, O. (2019, May 28). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus . https://doi.org/10.1161/ CIRCULATIONAHA.119.040130 • Khan, M. S., Samman Tahhan, A., Vaduganathan, M., Greene, S. J., Alrohaibani, A., Anker, S. D., Vardeny, O., Fonarow, G. C., & Butler, J. (2020). Trends in prevalence of comorbidities in
Page 38
Book Code: RPUS3024
EliteLearning.com/Pharmacy
Powered by FlippingBook